The advent of new targeted oral therapies to treat moderate-severe psoriasis generated anticipation about their impact on the existing biologic treatment paradigm. Top-level insights from Ipsos’ PsO Therapy Monitor highlight key physician-stated and real-world patient metrics to consider when planning for launch of a new asset or defending an existing asset in this market.
A series of three reports that brings the nasal polyps patient voice directly to pharma. Spanning 18 months, Ipsos’ Severe Nasal Polyps Patient Community provides unique visibility of patients’ unmet needs via an ongoing online panel of those living with the condition. Interactive activities focused on specific elements of their journey, offering insights to support a patient-centric strategy.
Since 2018, several new advanced therapies of differing mechanisms of action have been launched in the moderate-severe UC and CD treatment landscapes ‑ some being oral options. Top-level insights from Ipsos’ IBD Therapy Monitor highlight key physician-stated and real-world patient metrics to consider when planning for launch of a new asset or defending an existing asset in this market.
A series of five reports that brings the asthma patient voice directly to pharma. Conducted over two years, Ipsos’ Severe Asthma Patient Community offers unique visibility of patients’ unmet needs via an ongoing online panel of those living with the condition. Interactive activities focused on specific elements of the asthma patient journey, offering insights to support a patient-centric strategy.
A series of seven reports that brings the AD patient voice directly to pharma. Conducted over three years, Ipsos’ AD Patient & Caregiver Community offers unique visibility of patients’ unmet needs via an ongoing online panel of those living with the condition ‑ plus those caring for children with AD. Interactive activities focused on specific elements of the AD patient journey, offering insights to support a patient-centric strategy.